Classick v. Schell & Kampeter, Inc.

District Court, E.D. California·Decided May 19, 2021·No. 2:18-cv-02344·Unknown

Opinion

RICHARD DAVID CLASSICK, JR., No. 2:18-cv-02344-JAM-AC individually and on behalf of all others similarly situated, ORDER DENYING DEFENDANT’S MOTION Plaintiff, TO DISMISS v. SCHELL & KAMPETER, INC. d/b/a Defendant. Richard David Classick, Jr. (“Plaintiff”), the owner of a Blue Nose American Pitbull named Otis, purchased Taste of the Wild® dog food for his loyal companion until he discovered it contains undisclosed levels of heavy metals, BPA, pesticides, acrylamides and regrinds. Plaintiff brought a putative class action against Schell & Kampeter, Inc. d/b/a Diamond Pet Foods (“Defendant”), the company that manufactures, markets, and sells Taste of the Wild® dog food. See Fourth Am. Compl. (“4AC”), ECF No. 67. Defendant moves to dismiss. See Mot. to Dismiss (“Mot.”), ECF No. 70.1

1 This motion was determined to be suitable for decision without oral argument. E.D. Cal. L.R. 230(g). The hearing was scheduled for April 20, 2021. From approximately 2017 to 2018, Plaintiff purchased Taste of the Wild® Grain Free High Prairie Canine Formula Roasted Bison and Roasted Venison Dry Dog Food from Amazon.com. 4AC ¶ 18. Plaintiff reviewed the nutritional claims and labels displayed on Amazon’s website prior to purchasing the dog food. Id. From what he read on Amazon’s website, Plaintiff believed that he was feeding Otis a premium dog food that was healthy and nutritious. Id. Defendant markets the Taste of the Wild® brand as a “premium” dog food that is as “nature intended” and “based on your pet’s ancestral diet.” See 4AC ¶¶ 27–33. The Taste of the Wild® dog food also purports to use “the best nutrition available” and is “processed under strict human-grade standards to ensure purity.” See 4AC ¶¶ 34–35. What Plaintiff did not know was that the dog food contains some amount of heavy metals (including mercury, lead, arsenic, and cadmium), bisphenol A (“BPA”), pesticides, acrylamide, and regrinds. See 4AC ¶¶ 36–37, 65, 73, 80, 87, 91, 98, 101. That information is not included on the packaging. 4AC ¶ 36. Plaintiff, therefore, alleges that Defendant misleadingly assures consumers that its dog food undergoes stringent testing and quality controls and wrongfully fails to disclose to consumers the presence of contaminants. See 4AC ¶¶ 100, 102, 105. Plaintiff alleges that Defendant’s actions and omissions amount to negligent misrepresentation, violation of the California Consumer Legal Remedies Act (“CLRA”), and breach of the express warranty. See 4AC ¶¶ 174–204. Defendant moves to dismiss the 4AC in its entirety, arguing, among other things, that Plaintiff does not adequately plead actual or reasonable reliance and fails to allege a direct transaction. See generally Mot. Plaintiff opposes the motion. See Opp’n, ECF No. 77. A. Request for Judicial Notice Defendant requests that the Court take judicial notice of a copy of the Food and Drug Administration’s (“FDA”) Draft Guidance for Industry #245, Hazard Analysis and Risk-Based Preventive Controls for Food for Animals (Jan. 2018). See Req. for Judicial Notice (“RJN”), ECF No. 71. Plaintiff opposes this request. See Response to RJN, ECF No. 78. Judicial notice under Federal Rule of Evidence 201 permits a court to notice an adjudicative fact that is not subject to reasonable dispute. Khoja v. Orexigen Therapeutics, Inc., 899 F.3d 988, 999 (9th Cir. 2018). “A fact is not subject to reasonable dispute if it is generally known, or can be accurately and readily determined from sources whose accuracy cannot reasonably be questioned.” Id. (internal quotation marks and citation omitted). Thus, “a court may take judicial notice of matters of public record without converting a motion to dismiss into a motion for summary judgment.” Id. However, “a court cannot take judicial notice of disputed facts contained in such public records.” Id. “[A] publicly available FDA guidance document, is [] properly subject to judicial notice.” Immanuel Lake v. Zogenix, Inc., 2020 WL 3820424, at *5 (N.D. Cal. 2020). “[C]ourts routinely take judicial notice of [] FDA guidance documents, many of which also appear on the FDA’s public website.” Id. (citing Allen v. ConAgra Foods, Inc., 2018 WL 6460451, at *8 n.6 (N.D. Cal. 2018)). The FDA’s Draft Guidance for Industry #245 is currently accessible on the FDA’s website (specifically, at https://www.fda.gov/regulatory-information/search-fda-guidance- documents/cvm-gfi-245-hazard-analysis-and-risk-based-preventive- controls-food-animals) as of the date of this order. Thus, its “accuracy cannot reasonably be questioned,” making it subject to judicial notice. See Fed. R. Evid. 201(b). Accordingly, Defendant’s request for judicial notice is GRANTED. The Court takes judicial notice of the document’s existence. It does not take judicial notice of any disputed or irrelevant facts within the document. B. Legal Standard Generally, to defeat a Rule 12(b)(6) motion to dismiss, a plaintiff must “plead enough facts to state a claim to relief that is plausible on its face.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 570 (2007). However, where the claims sound in fraud (as claims of negligent misrepresentation and violations of the CLRA do), they must be pled with particularity pursuant to Rule 9(b). Kearns v. Ford Motor Co., 567 F.3d 1120, 1124–25 (9th Cir. 2009). “Averments of fraud must be accompanied by the who, what, when, where, and how of the misconduct charged.” Id. at 1124 (internal quotation marks and citation omitted). Claims of fraudulent omissions, like claims of fraudulent misrepresentations, are subject to Rule 9(b)’s heightened pleading standards. Id. at 1127. Where an omission is alleged, plaintiffs at a minimum must “describe the content of the omission and where the omitted information should or could have been revealed.” Marolda v. Symantec Corp., 672 F.Supp.2d 992, 1002 (N.D. Cal. 2009). C. Reasonable Reliance Defendant’s leading argument is that all three of Plaintiff’s claims fail because he has not pled facts supporting actual and reasonable reliance, a necessary element of each. See Mot. at 4–11; Shamsian v. Atlantic Richfield Co., 107 Cal.App.4th 967, 983 (2003) (“justifiable reliance on the misrepresentation by the party to whom it was directed” is a necessary element of negligent misrepresentation); Durrell v. Sharp Healthcare, 183 Cal.App.4th 1350, 1366–67 (2010) (under the CLRA, a “misrepresentation is material for a plaintiff only if there is reliance—that is, without the misrepresentation, the plaintiff would not have acted as he did.”); Nickerson v. Goodyear Tire and Rubber Corp., 2020 WL 4937561, at *5 (C.D. Cal. 2020) (for a breach of express warranty claim where the parties are not in privity, “California law requires a showing that a plaintiff relied on an alleged warranty.”). Put another way, Defendant argues that Plaintiff has not satisfied the “reasonable consumer standard,” which requires that Plaintiff “show[s] that members of the public are likely to be deceived.” Williams v. Gerber Prods., 552 F.3d 934, 938 (9th Cir. 2008). This requires more than a mere possibility that Defendant’s marketing “might conceivably be misunderstood by some few consumers viewing it in an unreasonable manner.” Becerra v. Dr Pepper/Seven Up, Inc., 945 F.3d 1225, 1228 (9th Cir. 2019) (internal quotation marks and citation omitted). Instead, it must be probable that “a significan

Free access — add to your briefcase to read the full text and ask questions with AI

Classick v. Schell & Kampeter, Inc., (E.D. Cal. 2021).

Classick v. Schell & Kampeter, Inc. (Classick v. Schell & Kampeter, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Southland Sod Farms v. Stover Seed Co.
108 F.3d 1134 (Ninth Circuit, 1997)
Kearns v. Ford Motor Co.
567 F.3d 1120 (Ninth Circuit, 2009)
Williams v. Gerber Products Co.
552 F.3d 934 (Ninth Circuit, 2008)
Newcal Industries, Inc. v. IKON Office Solution
513 F.3d 1038 (Ninth Circuit, 2008)
Schauer v. Mandarin Gems of California, Inc.
23 Cal. Rptr. 3d 233 (California Court of Appeal, 2005)
Durell v. Sharp Healthcare
183 Cal. App. 4th 1350 (California Court of Appeal, 2010)
Wilson v. Century 21 Great Western Realty
15 Cal. App. 4th 298 (California Court of Appeal, 1993)
Marolda v. Symantec Corp.
672 F. Supp. 2d 992 (N.D. California, 2009)
Chamberlan v. Ford Motor Co.
369 F. Supp. 2d 1138 (N.D. California, 2005)
Anunziato v. eMachines, Inc.
402 F. Supp. 2d 1133 (C.D. California, 2005)
Karim Khoja v. Orexigen Therapeutics, Inc.
899 F.3d 988 (Ninth Circuit, 2018)
Shana Becerra v. Dr pepper/seven Up, Inc.
945 F.3d 1225 (Ninth Circuit, 2019)
Collins v. eMachines, Inc.
202 Cal. App. 4th 249 (California Court of Appeal, 2011)
Lucido v. Nestle Purina Petcare Co.
217 F. Supp. 3d 1098 (N.D. California, 2016)
Zeiger v. Wellpet LLC
304 F. Supp. 3d 837 (N.D. California, 2018)